On Tuesday, ProQR Therapeutics N.V (NASDAQ: PRQR) was 5.84% up from the session before settling in for the closing price of $1.54. A 52-week range for PRQR has been $1.07 – $4.62.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 82.57% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at -27.19%. With a float of $70.76 million, this company’s outstanding shares have now reached $102.71 million.
In terms of profitability, gross margin is 92.57%, operating margin of -162.98%, and the pretax margin is -147.68%.
ProQR Therapeutics N.V (PRQR) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward ProQR Therapeutics N.V stocks. The insider ownership of ProQR Therapeutics N.V is 32.74%, while institutional ownership is 42.80%.
ProQR Therapeutics N.V (PRQR) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.17 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -27.19% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -19.10% during the next five years compared to 25.70% growth over the previous five years of trading.
ProQR Therapeutics N.V (NASDAQ: PRQR) Trading Performance Indicators
You can see what ProQR Therapeutics N.V (PRQR) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 3.95. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 8.39.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.35, a number that is poised to hit -0.10 in the next quarter and is forecasted to reach -0.57 in one year’s time.
Technical Analysis of ProQR Therapeutics N.V (PRQR)
Let’s dig in a bit further. During the last 5-days, its volume was 0.76 million. That was better than the volume of 0.5 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 84.68%. Additionally, its Average True Range was 0.13.
During the past 100 days, ProQR Therapeutics N.V’s (PRQR) raw stochastic average was set at 21.24%, which indicates a significant decrease from 86.15% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 90.76% in the past 14 days, which was higher than the 82.39% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.6846, while its 200-day Moving Average is $2.3169. However, in the short run, ProQR Therapeutics N.V’s stock first resistance to watch stands at $1.7233. Second resistance stands at $1.8167. The third major resistance level sits at $1.9133. If the price goes on to break the first support level at $1.5333, it is likely to go to the next support level at $1.4367. Assuming the price breaks the second support level, the third support level stands at $1.3433.
ProQR Therapeutics N.V (NASDAQ: PRQR) Key Stats
There are 105,213K outstanding shares of the company, which has a market capitalization of 171.50 million. As of now, sales total 20,460 K while income totals -30,040 K. Its latest quarter income was 4,610 K while its last quarter net income were -9,910 K.
